Safety and efficacy of insulin degludec/liraglutide (<scp>ID</scp>egLira) added to sulphonylurea alone or to sulphonylurea and metformin in insulin‐naïve people with Type 2 diabetes: the <scp>DUAL IV</scp> trial

W. Rodbard, Helena; W. Bode, Bruce; B. Harris, Stewart; Rose, Ludger; Lehmann, Lucine; Jarlov, Henrik; Thurman, Jerry; Dual Action of Liraglutide and insulin degludec (DUAL) IV trial investigators, the

doi:10.1111/dme.13256

Public

Safety and efficacy of insulin degludec/liraglutide (<scp>ID</scp>egLira) added to sulphonylurea alone or to sulphonylurea and metformin in insulin‐naïve people with Type 2 diabetes: the <scp>DUAL IV</scp> trial

Published in Diabetic Medicine • Sep 2, 2016

Authors:

Helena W. Rodbard

Bruce W. Bode

Stewart B. Harris

Abstract

Abstract Aim To investigate the safety and efficacy of insulin degludec/liraglutide ( ID egLira), a novel combination product, as add‐on therapy for people with Type 2 diabetes uncontrolled on sulphonylurea therapy. Methods In this 26‐week, double‐blind trial, adults with Type 2 diabetes [HbA 1c 53–...

View

Open Access

Subject

Liraglutide

Medicine

Metformin

Generate AI Take for this paper

Highlights, strengths & weaknesses, commercial applications, and societal impact — written for this paper on demand.

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!